Until very recently, the remaining gap in evidence has been dataon the safety and efficacy of SGLT2 inhibitors in patients with acute myocardialinfarction (MI) as former trials of SGLT2 inhibitors to date have excludedpatients with recent ischemic events. This evidence concerns the gene SLC5A2 and myocardial infarction.